Share on StockTwits

Oncomed Pharmaceuticals (NASDAQ:OMED) SVP Jakob Dupont sold 1,500 shares of the company’s stock on the open market in a transaction dated Thursday, June 26th. The shares were sold at an average price of $23.00, for a total value of $34,500.00. Following the completion of the sale, the senior vice president now directly owns 20,896 shares in the company, valued at approximately $480,608. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Several analysts have recently commented on the stock. Analysts at Mizuho reiterated a “buy” rating on shares of Oncomed Pharmaceuticals in a research note on Friday, June 13th. Separately, analysts at Zacks upgraded shares of Oncomed Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note on Tuesday, May 13th. They now have a $23.10 price target on the stock. Finally, analysts at Jefferies Group cut their price target on shares of Oncomed Pharmaceuticals from $50.00 to $48.00 in a research note on Friday, May 9th. One analyst has rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average target price of $37.78.

Oncomed Pharmaceuticals (NASDAQ:OMED) opened at 24.00 on Wednesday. Oncomed Pharmaceuticals has a 1-year low of $12.07 and a 1-year high of $42.34. The stock has a 50-day moving average of $23.30 and a 200-day moving average of $29.07. The company’s market cap is $709.3 million.

Oncomed Pharmaceuticals (NASDAQ:OMED) last announced its earnings results on Thursday, May 8th. The company reported ($0.47) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.13) by $0.34. Analysts expect that Oncomed Pharmaceuticals will post $-0.76 EPS for the current fiscal year.

OncoMed Pharmaceuticals, Inc (NASDAQ:OMED) is a clinical development-stage biopharmaceutical company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.